[go: up one dir, main page]

MX2021001264A - Métodos para tratar la vejiga hiperactiva con el uso de trospio. - Google Patents

Métodos para tratar la vejiga hiperactiva con el uso de trospio.

Info

Publication number
MX2021001264A
MX2021001264A MX2021001264A MX2021001264A MX2021001264A MX 2021001264 A MX2021001264 A MX 2021001264A MX 2021001264 A MX2021001264 A MX 2021001264A MX 2021001264 A MX2021001264 A MX 2021001264A MX 2021001264 A MX2021001264 A MX 2021001264A
Authority
MX
Mexico
Prior art keywords
methods
trospium
overactive bladder
bladder
treating overactive
Prior art date
Application number
MX2021001264A
Other languages
English (en)
Inventor
Dennis Giesing
Original Assignee
Taris Biomedical Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taris Biomedical Llc filed Critical Taris Biomedical Llc
Publication of MX2021001264A publication Critical patent/MX2021001264A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M31/00—Devices for introducing or retaining media, e.g. remedies, in cavities of the body
    • A61M31/002—Devices for releasing a drug at a continuous and controlled rate for a prolonged period of time
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/06—Anti-spasmodics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00—General characteristics of the apparatus
    • A61M2205/02—General characteristics of the apparatus characterised by a particular materials
    • A61M2205/0216—Materials providing elastic properties, e.g. for facilitating deformation and avoid breaking
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00—General characteristics of the apparatus
    • A61M2205/02—General characteristics of the apparatus characterised by a particular materials
    • A61M2205/0266—Shape memory materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2210/00—Anatomical parts of the body
    • A61M2210/10—Trunk
    • A61M2210/1078—Urinary tract
    • A61M2210/1085—Bladder

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Emergency Medicine (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
  • Materials For Medical Uses (AREA)

Abstract

La presente solicitud proporciona métodos para tratar la vejiga hiperactiva y métodos para entrenar o reentrenar la vejiga, prolongar el alivio de síntomas, mejorar la calidad de vida y/o para el remodelado neuronal en un individuo que tiene vejiga hiperactiva, mediante la administración de una cantidad eficaz de trospio localmente a la vejiga del individuo durante al menos aproximadamente 24 horas.
MX2021001264A 2018-08-01 2019-07-31 Métodos para tratar la vejiga hiperactiva con el uso de trospio. MX2021001264A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862713414P 2018-08-01 2018-08-01
US201962850481P 2019-05-20 2019-05-20
PCT/US2019/044478 WO2020028554A1 (en) 2018-08-01 2019-07-31 Methods of treating overactive bladder using trospium

Publications (1)

Publication Number Publication Date
MX2021001264A true MX2021001264A (es) 2021-07-02

Family

ID=69232612

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021001264A MX2021001264A (es) 2018-08-01 2019-07-31 Métodos para tratar la vejiga hiperactiva con el uso de trospio.

Country Status (10)

Country Link
US (2) US11464734B2 (es)
EP (1) EP3829582A4 (es)
JP (2) JP2021532155A (es)
KR (1) KR20210039403A (es)
CN (1) CN112839653A (es)
AU (1) AU2019315957A1 (es)
BR (1) BR112021001337A2 (es)
CA (1) CA3107461A1 (es)
MX (1) MX2021001264A (es)
WO (1) WO2020028554A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018306299B2 (en) 2017-07-25 2024-08-08 Taris Biomedical Llc Methods of treating tumor metastasis
US10792297B2 (en) 2017-11-08 2020-10-06 Taris Biomedical Llc Methods of treatment and maintenance therapy for bladder cancer using gemcitabine
MX2021001264A (es) 2018-08-01 2021-07-02 Taris Biomedical Llc Métodos para tratar la vejiga hiperactiva con el uso de trospio.

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0856312B1 (de) 1996-11-27 1998-10-14 Dr. R. Pfleger Chemische Fabrik GmbH Verwendung von Trospiumchlorid zur Herstellung eines Arzneimittels zur Behandlung von Blasenkrankheiten
MX2013000002A (es) * 2001-07-27 2013-04-29 Teva Womens Health Inc Metodos de tratamiento de condiciones patologicas asociadas con vejiga hiperactiva.
EP1572279A1 (en) 2002-12-11 2005-09-14 Coloplast A/S A urinary catheter device with a pharmaceutically active composition
CA2513188A1 (en) 2003-01-16 2004-08-05 University Of Rochester Quaternary antimuscarinic compounds for the treatment of bladder diseases
WO2005067890A2 (en) 2004-01-13 2005-07-28 Vasogenix Pharmaceuticals, Inc. Controlled release cgrp delivery composition for cardiovascular and renal indications
ES2322148T3 (es) 2004-08-11 2009-06-17 BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG Medicamentos que contienen anticolinergicos para el tratamiento en las vias urinarias.
US20060128808A1 (en) * 2004-10-20 2006-06-15 Galderma Research & Development, S.N.C. Method of using adapalene in acne maintenance therapy
US20060217405A1 (en) 2005-03-17 2006-09-28 Indevus Pharmaceuticals, Inc. Interstitial cystitis treatment
US7390816B2 (en) * 2005-06-21 2008-06-24 Bridge Pharma, Inc. Methods for treating urinary incontinence in patients suffering from memory disorders
EP1933810B1 (en) 2005-08-11 2012-10-10 Massachusetts Institute of Technology Intravesical drug delivery device and method
CN103142586A (zh) 2005-09-02 2013-06-12 塞拉维达公司 治疗疾病的疗法
EP1967202A1 (en) 2007-03-05 2008-09-10 AEterna Zentaris GmbH Use of LHRH Antagonists for the Treatment of Lower Urinary Tract Symptoms, in particular Overactive Bladder and/or Detrusor Overactivity
ES2481454T3 (es) 2007-12-11 2014-07-30 Massachusetts Institute Of Technology Dispositivo implantable de administración de fármacos
JP5908279B2 (ja) 2008-08-09 2016-04-26 マサチューセッツ インスチテュート オブ テクノロジーＭａｓｓａｃｈｕｓｅｔｔｓ Ｉｎｓｔｉｔｕｔｅ Ｏｆ Ｔｅｃｈｎｏｌｏｇｙ 移植可能な薬物送達デバイス並びに男性の尿生殖器及び周囲組織を治療する方法
AU2010265866B2 (en) 2009-06-26 2012-07-12 Taris Biomedical Llc Solid drug tablets for implantable drug delivery devices
US9017312B2 (en) 2009-09-10 2015-04-28 Taris Biomedical Llc Implantable device for controlled drug delivery
ES2867399T3 (es) 2009-12-17 2021-10-20 Taris Biomedical Llc Dispositivo implantable con tolerabilidad intravesical
RS61074B1 (sr) 2010-08-05 2020-12-31 Taris Biomedical Llc Ureteralno stent sredstvo za isporuku leka i kit
US8690840B2 (en) 2010-10-06 2014-04-08 Taris Biomedical, Inc. Time-selective bioresorbable or collapsible drug delivery systems and methods
EP2663300B1 (en) 2011-01-10 2023-03-08 TARIS Biomedical LLC Lidocaine regimen for the use of sustained treatment of bladder pain and irritative voiding
EP2670398B1 (en) 2011-02-04 2017-06-07 TARIS Biomedical LLC Implantable device for controlled release of low solubility drug
BR112015004110A2 (pt) 2012-08-31 2017-07-04 Taris Biomedical Llc sistemas e métodos de distribuição de drogas para tratamento de próstata
ES2902833T3 (es) 2012-08-31 2022-03-30 Taris Biomedical Llc Sistemas y métodos de administración de fármacos para el tratamiento de cáncer de vejiga que comprenden oxaliplatino
WO2014047221A1 (en) * 2012-09-18 2014-03-27 Taris Biomedical, Inc. Drug delivery systems and methods for treatment of bladder voiding dysfunction|and other lower urinary tract disorders by using trospium
EP2719374A1 (en) * 2012-10-12 2014-04-16 Rheinisch-Westfälische Technische Hochschule (RWTH) Aachen Drug delivery device
JP2016508842A (ja) 2013-03-05 2016-03-24 タリス バイオメディカル エルエルシー 装置の開口部を通じて制御された薬物放出のための薬物送達装置及び方法
NZ711416A (en) 2013-03-15 2018-02-23 Taris Biomedical Llc Drug delivery devices and methods for drug delivery
EP2968880B1 (en) 2013-03-15 2025-04-30 TARIS Biomedical LLC Drug delivery devices with drug-permeable component
HRP20201421T1 (hr) 2013-08-19 2020-12-11 Taris Biomedical Llc Uređaji za davanje više jedinica lijeka
BR112016010103A8 (pt) 2013-11-05 2018-01-30 Taris Biomedical Llc métodos, kits e dispositivos de suprimento de fármaco osmótico.
RS63675B1 (sr) 2014-03-06 2022-11-30 Taris Biomedical Llc Sistemi za isporuku leka i metode za lečenje raka bešike gemcitabinom
WO2015200752A1 (en) 2014-06-26 2015-12-30 Taris Biomedical Llc Intravesical drug delivery devices and methods including elastic polymer-drug matrix systems
EP3285850A1 (en) 2015-04-23 2018-02-28 TARIS Biomedical LLC Drug delivery devices with drug-permeable component and methods
WO2017042370A1 (en) * 2015-09-10 2017-03-16 Assistance Publique - Hôpitaux De Paris Use of interleukin 2 for treating spondyloarthritis
JP6283440B1 (ja) * 2016-10-27 2018-02-21 Ｅａファーマ株式会社 逆流性食道炎の再発抑制剤
EP3432970B1 (en) * 2017-02-01 2021-03-24 TARIS Biomedical LLC In vivo drug delivery devices
AU2018306299B2 (en) 2017-07-25 2024-08-08 Taris Biomedical Llc Methods of treating tumor metastasis
MX2021001264A (es) 2018-08-01 2021-07-02 Taris Biomedical Llc Métodos para tratar la vejiga hiperactiva con el uso de trospio.

Also Published As

Publication number Publication date
EP3829582A4 (en) 2022-04-27
WO2020028554A1 (en) 2020-02-06
AU2019315957A1 (en) 2021-02-18
US20200060966A1 (en) 2020-02-27
BR112021001337A2 (pt) 2021-04-20
JP2024164020A (ja) 2024-11-26
US11464734B2 (en) 2022-10-11
US20230075003A1 (en) 2023-03-09
JP2021532155A (ja) 2021-11-25
EP3829582A1 (en) 2021-06-09
CN112839653A (zh) 2021-05-25
CA3107461A1 (en) 2020-02-06
KR20210039403A (ko) 2021-04-09
US12133913B2 (en) 2024-11-05

Similar Documents

Publication Publication Date Title
WO2019246262A3 (en) Methods of treating or inhibiting onset of huntington's disease
EP4218804A3 (en) Use of myostatin inhibitors and combination therapies
MX2020008906A (es) Compuestos con actividad inductora de ferroptosis y métodos de uso de estos.
EP4371554A3 (en) Use of sublingual dexmedetomidine for the treatment of agitation
MX2019013279A (es) Metodos de tratamiento del sindrome de doose utilizando fenfluramina.
JOP20200035A1 (ar) تركيبات حمض أميني لعلاج الإصابات العصبية
MX2021001264A (es) Métodos para tratar la vejiga hiperactiva con el uso de trospio.
PH12020552088A1 (en) Vmat2 inhibitor compounds, compositions, and methods relating thereto
MX2021010173A (es) Compuestos con actividad inductora de ferroptosis y métodos de uso.
PH12019502174A1 (en) Modulators of pcsk9 expression
MY194462A (en) Composition for Promoting Differentiation of and Protecting Neural Stem Cells and Method for Inducing Neural Regeneration using same
MX2025003294A (es) Moduladores de la expresion de apol1
EP4285993A3 (en) Growth differentiation factor 15 as biomarker for metformin
MX2020007369A (es) Moduladores de la expresion de dnm2.
MX2020010302A (es) Uso de ácido (1s,3s)-3-amino-4-(difluorometilideno)ciclopentano-1- carboxílico y ácido (s)-3-amino-4-(difluorometilenil)ciclopent-1-e no-1-carboxílico en eltratamiento contra trastornos oculares.
AU2018282105A1 (en) Dosing of vibegron for treatment of overactive bladder
MX2021002754A (es) Tratamiento del autismo y trastornos dentro del espectro del autismo con composiciones de biotina.
MX2022004524A (es) Tratamiento génico para la enfermedad de alzheimer.
PH12021551975A1 (en) Use of vibegron to treat overactive bladder
PH12021551053A1 (en) Modulators of irf5 expression
PH12021550741A1 (en) Vibegron for the treatment of overactive bladder symptoms
MX2021011598A (es) Uso de mir101 o mir128 en el tratamiento de trastornos convulsivos.
MX2022012366A (es) Metodos para generar neuronas de dopamina del mesencefalo, neuronas del mesencefalo, y usos de las mismas.
MY202857A (en) Method of treating hyperglycemia
MX2017007207A (es) Tratamiento de afecciones oculares mediante el uso de celulas progenitoras.